Omega Funds has led a $16m round for Switzerland-based Chord Therapeutics, a biopharmaceutical company that develops treatments for rare and life-threatening diseases.
Omega Funds has led a $16m round for Switzerland-based Chord Therapeutics, a biopharmaceutical company that develops treatments for rare and life-threatening diseases.